You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca and MedImmune has announced positive overall survival (OS) results for the Phase III PACIFIC trial, a randomised, double-blinded, placebo-controlled, multi-centre trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease had Already a subscriber Login You have read all your free articles, to continue…
The company has announced the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans. The findings was announced at the European Society of Cardiology (ESC) Congress 2019 in Paris,Already a subscriber Login You have read all…
IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time without troublesome dyskinesia, as assessed with patient diaries, did not reach sAlready a subscriber Login You have read all your…
New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information. The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO PhaAlready a subscriber Login You have read all your free articles, to continue reading subscribe to…
